GSK press releases
Follow
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Findings could help inform expectations and decision-making when initiating long-acting HIV injectables
